Literature DB >> 2786510

The prevalence of antibody to p42 of HTLV-I among ATLL patients in comparison with healthy carriers in Japan.

T Yokota1, M J Cho, N Tachibana, M F McLane, K Takatsuki, T H Lee, N Mueller, M Essex.   

Abstract

A gene product (p42) of the long open reading frame, now termed tax, of the viral genome of human T-cell leukemia virus type I (HTLV-I) may be related to the transformation of T cells in adult T-cell leukemia-lymphoma (ATLL). To evaluate its association with the disease, we compared the prevalence of antibody to p42 in sera obtained from 105 HTLV-I carriers and 64 ATLL patients from southwest Japan. The prevalence of the anti-p42 antibody reactivity was 63% among carriers and 31% among cases. The cases were more than 3 times as likely to lack antibody to p42 than carriers, the relative odds (OR) = 3.4, p = 0.001. When the samples were tested for antibody against p24, the most immunogenic core protein, the prevalence was somewhat higher among carriers (65%) than in cases (52%), but not significantly so (p = 0.15). Among the healthy carriers, the correlation between the prevalence of both antibodies was high (p = 0.001), and only 25% of those who had antibody to p24 lacked antibody to p42. However, among the cases, reactivity to both antigens was independent (p = 0.52), and 65% of those with antibody to p24 lacked antibody to p42, OR = 6.3, p = 0.0004. Thus the strongest serologic marker of ATLL following diagnosis was lack of reactivity to p42, particularly among those subjects with anti-p24. Whether this altered response is present prior to disease remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2786510     DOI: 10.1002/ijc.2910430603

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Quantitative differences in HTLV-I antibody responses: classification and relative risk assessment for asymptomatic carriers and ATL and HAM/TSP patients from Jamaica.

Authors:  Yoshimi Enose-Akahata; Anna Abrams; Kory R Johnson; Elizabeth M Maloney; Steven Jacobson
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

Review 2.  The epidemiology of HTLV-I infection.

Authors:  N Mueller
Journal:  Cancer Causes Control       Date:  1991-01       Impact factor: 2.506

3.  In vivo genomic variability of human T-cell leukemia virus type I depends more upon geography than upon pathologies.

Authors:  F Komurian; F Pelloquin; G de Thé
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

4.  Population differences in immune marker profiles associated with human T-lymphotropic virus type I infection in Japan and Jamaica.

Authors:  Brenda M Birmann; Elizabeth C Breen; Sherri Stuver; Beverly Cranston; Otoniel Martínez-Maza; Kerstin I Falk; Akihiko Okayama; Barrie Hanchard; Nancy Mueller; Michie Hisada
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

5.  Episodic occurrence of antibodies against the bovine leukemia virus Rex protein during the course of infection in sheep.

Authors:  M A Powers; D Grossman; L C Kidd; K Radke
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

6.  Detection of antibodies to trans-activator protein (p40taxI) of human T-cell lymphotropic virus type I by a synthetic peptide-based assay.

Authors:  D L Rudolph; J E Coligan; R B Lal
Journal:  Clin Diagn Lab Immunol       Date:  1994-03

7.  Anti-HTLV antibody profiling reveals an antibody signature for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Authors:  Peter D Burbelo; Elise Meoli; Hannah P Leahy; Jhanelle Graham; Karen Yao; Unsong Oh; John E Janik; Renaud Mahieux; Fatah Kashanchi; Michael J Iadarola; Steven Jacobson
Journal:  Retrovirology       Date:  2008-10-20       Impact factor: 4.602

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.